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The complete amino acid sequence of an amyloidogenic Bence Jones protein(NIG-84) from an individual 
with myeloma-associated systemic amyloidosis has been determined. The protein, with a blocked N-termi- 
nus, represents a complete light chain consisting of 2 17 residues and it has a structural feature characteristic 
of the Vi II subgroup. In addition to a two-residue insertion at positions 28 and 29, it has an additional 
rare insertion of alanine at position 100. NIG-84 is an example of the first complete sequence presented 
for the amyloidogenic Bence Jones protein of the V1 II subgroup. 
Amyloidosis Bence Jones protein Primary structure Subgroup Amyloidogenicitl 
1. INTRODUCTION 
It is now accepted that immunoglobulin light 
chain fragments (AL), or less commonly whole 
chains, consist of the major part of the amyloid 
fibrils in primary and myeloma-associated 
systemic amyloidoses, as well as in some forms of 
localized amyloidosis [ 1,2]. However, because of 
the limited and rather incomplete sequence data, it 
is not yet possible to elucidate the ‘amyloidogenici- 
ty’ of such proteins in relation to their primary 
structure, though AL proteins of certain 
subgroups have been reported to be more prone to 
association with the amyloid process [3-61. Since 
only a fraction of the immunoglobulin light chains 
seems to be involved in amyloidogenesis, their se- 
quence characteristics may be an essential clue to 
understanding of amyloid fibril formation in the 
disease. 
This paper presents the complete amino acid se- 
quence of the amyloidogenic A Bence Jones Pro- 
tein (BJP) NIG-84 in myeloma-associated systemic 
amyloidosis and shows a unique structural feature 
* To whom correspondence should be addressed 
which may give some insights into the 
amyloidogenicity of the light chains. 
2. MATERIALS AND METHODS 
2.1. Purification of NIG-84 
Protein NIG-84 was isolated from the urine of a 
patient with multiple myeloma-associated amy- 
loidosis as follows: (i) fractionation with 65% 
saturation of (NH4)&04; (ii) DEAE-Sephadex 
A-50 column chromatography [8 x 11 cm, in 
10 mM Tris-HCl, pH 8.5, with a linear gradient in 
NaCl (O-O.3 M)]; (iii) gel filtration on a column of 
Sephadex G-100 (2.6 x 70 cm, in 0.1 M Tris-HCI, 
pH 8.1, containing 0.15 M NaCI); (iv) reverse- 
phase high-performance liquid chromatography 
(HPLC) with Hitachi Gel 3013-O (0.4 x 25 cm, in 
20% CH$N, 0.1% trifluoroacetic acid (TFA), pH 
2.5, with a linear gradient in an increasing concen- 
tration of CHjCN (20-75%), 0.1% TFA, pH 2.5 
[6,71). 
2.2. Trypsin digestion and purification of the 
peptides 
Following complete reduction with 2-mercap- 
toethanol and aminoethylation with ethylenei- 
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mine [3,7], NIG-84 (25 mg in 10 ml of 20 mM duced by the analysis of 20 distinct tryptic peptides 
NH4HC03) was digested with 1.25 mg TPCK- purified as above. It began with a blocked N- 
trypsin (2 x crystallized, Worthington) and treated terminus and consisted of 217 residues, indicating 
as in [6-81. The digest was chromatographed first that it was a complete light chain form. Of the 217 
by cation-exchange HPLC with Hitachi Gel residues, the V region consisted of the first 112 
3013-C (0.4 x 25 cm, in 0.5% CH3CN, 25% residues, the remainder being the C region. When 
isopropanol, 4 mM NH~CH~SOA, pH 6.4). The the sequence of the V region was compared with 
column was eluted at a flow rate of 0.5 ml/min at those of the reported A chains, it was most 
70°C with a linear gradient in an increasing con- homologous with that of the V h II subgroup 
centration of the initial buffer (to 50% CHjCN, (72-86%), thus it was tentatively classified into 
25% isopropanol, 0.4 M NHdCH3S04, pH 6.4). this subgroup. This was the first specimen among 
Peptides were further purified, if needed, by the amyloidogenic h BJPs whose sequence was 
reverse-phase HPLC as described [6,8]. identified as V h II subgroup. 
2.3. Sequence analysis 
Sequence analysis of the peptides (15-60 nmol) 
was carried out by manual Edman degradation and 
the resulting PTH-amino acids were identified by 
HPLC under the reported conditions [3,6-81. 
Digestions with carboxypeptidase A and/or B, and 
hydrazinolysis were performed as in [3,7]. The 
nomenclature of the peptides of the protein fol- 
lowed that adopted for other h chains [3,9]. 
3. RESULTS AND DISCUSSION 
The complete amino acid sequence of protein 
NIG-84 is shown in fig.1. The sequence was de- 
Fig.1. The proposed amino acid sequence for an 
amyloidogenic Bence Jones protein NIG-84. One-letter 
code for amino acids: A, Ala; C, Cys; D, Asp; E, Glu; 
F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; 
N, Asn; 0, Pea; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; 
V, Val; W, Trp; Y, Tyr. 
Although the NIG-84 sequence is most 
homologous with that of the V X II subgroup, it 
also has individual characteristics: (i) whereas all 
the reported V h II specimens have a tyrosine 
residue at position 93, NIG-84 has phenylalanine; 
(ii) insertion of an extra alanine residue at position 
100; (iii) a rare replacement of serine for threonine 
at position 109, near the V-C junction. On the 
basis of these data, the reported V A II specimens 
together with NIG-84, can be classified into the 
alternate subset, provisionally designated sub- 
subgroups V A IIa and V X IIb as exemplified by us 
for the V A I subgroup [lo], and by others for V H 
III subgroup [l 11. In these cases, all the specimens 
of ALs and BJPs, but not in those without 
amyloidosis, were shown to have either insertion 
of an extra amino acid residue(s) and/or an un- 
common sequence including very rare replacement 
at one or more positions. These structural 
characteristics probably cause local distortions in 
the conformation of these proteins, and these in 
turn might lead to their being more prone to 
association with the amyloid process. However, it 
is not yet possible to identify definitely any specific 
sequence or sequences which is essential for the 
amyloidogenicity of such proteins. Apparently fur- 
ther sequence data must be obtained before clarify- 
ing the problem. 
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